This pilot study will test the feasibility of using nanopore sequencing for breast cancer diagnosis in Tanzania. It aims to show that nanopore sequencing is non-inferior to the current standard of care, with the potential for faster and more cost-efficient results. By enhancing the speed and accuracy of diagnosis, this approach could improve treatment planning and outcomes for patients in resource-limited settings.
Patient with suspected diagnosis of breast cancer undergoing biopsy or surgical resection after specialist consultation as per institutional guidelines
Excess fresh tumor sample
Written informed consent
Unable to provide informed consent
Patients who have already commenced therapy for BC (except for treatment other than biomedicine, e.g. herbal medicines)
University of Bonn
Lead sponsor
German Cancer Research Center
Collaborator
Kilimanjaro Christian Medical Centre,Moshi,Tanzania
Collaborator